Cargando…
M1 muscarinic acetylcholine receptor dysfunction in moderate Alzheimer’s disease pathology
Aggregation of amyloid beta and loss of cholinergic innervation in the brain are predominant components of Alzheimer’s disease pathology and likely underlie cognitive impairment. Acetylcholinesterase inhibitors are one of the few treatment options for Alzheimer’s disease, where levels of available a...
Autores principales: | Yi, Jee Hyun, Whitcomb, Daniel J, Park, Se Jin, Martinez-Perez, Celia, Barbati, Saviana A, Mitchell, Scott J, Cho, Kwangwook |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7391992/ https://www.ncbi.nlm.nih.gov/pubmed/32766549 http://dx.doi.org/10.1093/braincomms/fcaa058 |
Ejemplares similares
-
Targeting the M1 muscarinic acetylcholine receptor in Alzheimer’s disease
por: Dwomoh, Louis, et al.
Publicado: (2022) -
Allosteric Modulation of Muscarinic Acetylcholine Receptors
por: Gregory, Karen J, et al.
Publicado: (2007) -
Allosteric Modulation of Muscarinic Acetylcholine Receptors
por: Jakubík, Jan, et al.
Publicado: (2010) -
Molecular properties of muscarinic acetylcholine receptors
por: HAGA, Tatsuya
Publicado: (2013) -
Evolution of the Muscarinic Acetylcholine Receptors in Vertebrates
por: Pedersen, Julia E., et al.
Publicado: (2018)